Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 174 results
September 2021
-
Media ReleaseNovartis data show rapid and effective disease activity control with remibrutinib (LOU064) in patients with chronic spontaneous urticariaResults from a Phase IIb study show all remibrutinib doses provided significant improvements in UAS7 change from baseline at week 4 and week 12 compared to placebo, and a favorable safety profile…
-
Media ReleaseNew data reinforce efficacy and convenience of Novartis Cosentyx® (secukinumab) 300 mg autoinjector in adults with psoriasisNew findings show Cosentyx® (secukinumab) 300 mg single dose autoinjector (the UnoReady® pen) resulted in superior efficacy vs placebo1 Patient satisfaction with 300 mg autoinjector…
-
Media ReleaseNovartis data show achieving complete control of chronic spontaneous urticaria (CSU) improves overall quality of life, as reported by patientsData analysis shows that preventing the symptoms of CSU (achieving complete control) improves overall health-related quality of life (HRQoL); including sleep and work productivity, among other…
June 2021
-
Media ReleaseNovartis presents positive Phase III results from JUNIPERA study supporting Cosentyx® as a potential treatment in a JIA population at EULAR 2021Phase III JUNIPERA study met its primary endpoint, with Cosentyx® (secukinumab) showing significantly longer time to flare (longer time to worsening of symptoms1) vs. placebo (P<.001) in pediatric…
-
Media ReleaseNovartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasisApproval for moderate to severe pediatric patients six years and older is based on pivotal trial data showing Cosentyx demonstrated superior improvements of skin symptoms compared to placebo1…
October 2020
-
Media ReleaseNovartis expands Kymriah® manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in AsiaFoundation for Biomedical Research and Innovation (FBRI) in Kobe, Japan becomes first CAR-T cell therapy commercial manufacturing site in Asia Novartis global CAR-T manufacturing footprint now…
-
Media ReleaseNovartis presents latest Phase III data reinforcing Cosentyx® as a first-line systemic treatment in pediatric psoriasisLatest data show Cosentyx® provides fast and strong skin clearance, significant improvement in quality of life and a favorable safety profile1,2 Moderate-to-severe psoriasis affects more than…
Pagination
- ‹ Previous page
- 1
- …
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- …
- 15
- › Next page